Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 quercetin studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 56% 5 936 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 46% 3 623 ICU admission 90% 3 623 Hospitalization 68% 2 194 Recovery 43% 2 629 Cases 92% 1 113 Viral clearance 74% 1 42 RCTs 56% 5 936 Peer-reviewed 34% 4 823 Prophylaxis 92% 1 113 Early 79% 2 194 Late 24% 2 629 Quercetin for COVID-19 c19quercetin.com Dec 3, 2021 Favors quercetin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] death 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.02-1.82] 0/97 4/97 79% improvement Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Improvement, RR [CI] Treatment Control Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Tau​2 = 0.00; I​2 = 0.0% Late treatment 24% 0.76 [0.36-1.62] 10/148 19/481 24% improvement Arslan (RCT) 92% 0.08 [0.01-0.79] cases 1/71 9/42 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 92% 0.08 [0.01-0.79] 1/71 9/42 92% improvement All studies 56% 0.44 [0.17-1.13] 11/316 32/620 56% improvement 5 quercetin COVID-19 studies c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.29; I​2 = 23.5%; Z = 1.70 Effect extraction pre-specified Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.02-1.82] 0/97 4/97 79% improvement Onal (RCT) -29% 1.29 [0.16-10.5] 1/49 6/380 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -29% 1.29 [0.16-10.5] 1/49 6/380 -29% improvement All studies 46% 0.54 [0.12-2.40] 1/146 10/477 46% improvement 3 quercetin COVID-19 mortality results c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.81 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 94% 0.06 [0.00-1.00] 0/76 8/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 87% 0.13 [0.02-1.05] 0/97 9/97 87% improvement Onal (RCT) 94% 0.06 [0.00-0.98] 0/49 14/380 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 94% 0.06 [0.00-0.98] 0/49 14/380 94% improvement All studies 90% 0.10 [0.02-0.52] 0/146 23/477 90% improvement 3 quercetin COVID-19 ICU results c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.71 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 68% 0.32 [0.14-0.70] hosp. 7/76 22/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] hosp. 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 68% 0.32 [0.15-0.69] 7/97 23/97 68% improvement All studies 68% 0.32 [0.15-0.69] 7/97 23/97 68% improvement 2 quercetin COVID-19 hospitalization results c19quercetin.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.93 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] death 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.02-1.82] 0/97 4/97 79% improvement Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -29% 1.29 [0.16-10.5] 1/49 6/380 -29% improvement All studies 46% 0.54 [0.12-2.40] 1/146 10/477 46% improvement 3 quercetin COVID-19 serious outcomes c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.81 Effect extraction pre-specified Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Onal (RCT) 78% 0.22 [0.03-1.58] no disch. 1/49 35/380 CT​1 Improvement, RR [CI] Treatment Control Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Tau​2 = 0.09; I​2 = 12.7% Late treatment 43% 0.57 [0.23-1.38] 10/148 48/481 43% improvement All studies 43% 0.57 [0.23-1.38] 10/148 48/481 43% improvement 2 quercetin COVID-19 recovery results c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.09; I​2 = 12.7%; Z = 1.25 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Arslan (RCT) 92% 0.08 [0.01-0.79] 1/71 9/42 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 92% 0.08 [0.01-0.79] 1/71 9/42 92% improvement All studies 92% 0.08 [0.01-0.63] 1/71 9/42 92% improvement 1 quercetin COVID-19 case result c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.40 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 74% 0.26 [0.12-0.57] viral+ 5/21 19/21 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 74% 0.26 [0.12-0.57] 5/21 19/21 74% improvement All studies 74% 0.26 [0.12-0.57] 5/21 19/21 74% improvement 1 quercetin COVID-19 viral clearance result c19quercetin.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.37 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] death 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.02-1.82] 0/97 4/97 79% improvement Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Improvement, RR [CI] Treatment Control Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Tau​2 = 0.00; I​2 = 0.0% Late treatment 24% 0.76 [0.36-1.62] 10/148 19/481 24% improvement Arslan (RCT) 92% 0.08 [0.01-0.79] cases 1/71 9/42 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 92% 0.08 [0.01-0.79] 1/71 9/42 92% improvement All studies 56% 0.44 [0.17-1.13] 11/316 32/620 56% improvement 5 quercetin COVID-19 Randomized Controlled Trials c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.29; I​2 = 23.5%; Z = 1.70 Effect extraction pre-specified Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.02-1.82] 0/97 4/97 79% improvement Onal (RCT) -29% 1.29 [0.16-10.5] 1/49 6/380 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -29% 1.29 [0.16-10.5] 1/49 6/380 -29% improvement All studies 46% 0.54 [0.12-2.40] 1/146 10/477 46% improvement 3 quercetin COVID-19 RCT mortality results c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.81 Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 67% 0.33 [0.01-7.74] death 0/21 1/21 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.02-1.82] 0/97 4/97 79% improvement Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Improvement, RR [CI] Treatment Control Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Tau​2 = 0.00; I​2 = 0.0% Late treatment 24% 0.76 [0.36-1.62] 10/148 19/481 24% improvement All studies 34% 0.66 [0.33-1.35] 10/245 23/578 34% improvement 4 quercetin COVID-19 peer reviewed trials c19quercetin.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.13 Effect extraction pre-specified Favors quercetin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 94% 0.06 [0.00-1.00] ICU 0/76 8/76 Di Pierro (RCT) 68% 0.32 [0.14-0.70] hosp. 7/76 22/76 Di Pierro (RCT) 67% 0.33 [0.01-7.74] death 0/21 1/21 Di Pierro (RCT) 67% 0.33 [0.01-7.74] ICU 0/21 1/21 Di Pierro (RCT) 67% 0.33 [0.01-7.74] hosp. 0/21 1/21 Di Pierro (RCT) 74% 0.26 [0.12-0.57] viral+ 5/21 19/21 Di Pierro (RCT) 89% 0.11 [0.01-1.94] viral+ 0/21 4/21 Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Onal (RCT) 94% 0.06 [0.00-0.98] ICU 0/49 14/380 CT​1 Onal (RCT) 78% 0.22 [0.03-1.58] no disch. 1/49 35/380 CT​1 Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Zupanets (RCT) 18% 0.82 [0.68-0.98] recov. time 99 (n) 101 (n) Arslan (RCT) 92% 0.08 [0.01-0.79] cases 1/71 9/42 CT​1 quercetin COVID-19 outcomes c19quercetin.com Dec 3, 2021 Favors quercetin Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit